Yanhong Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yanhong Chen has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Jiao Zhang
Division of Rheumatology, Xuzhou Central Hospital, Southeast University, Xuzhou , China
3 shared publicationsHongyuan Li
Department of neurology, Xuzhou Central Hospital, Xuzhou, Jiangsu, People’s Republic of China
2 shared publicationsJia Liu
Department of Clinical Laboratory, Xuzhou Central Hospital, Xuzhou, Jiangsu, People’s Republic of China
2 shared publicationsJian Li
Department of Clinical Laboratory, Xuzhou Central Hospital, Xuzhou, Jiangsu, People’s Republic of China
2 shared publicationsPeng Wang
Department of Clinical Laboratory, Xuzhou Central Hospital, Southeast University, Xuzhou, China
2 shared publicationsShiliang Wang
Department of obstetrics and gynecology of Xuzhou Central Hospital, Xuzhou, Jiangsu, People’s Republic of China
2 shared publications
Latest Publications
- Open Access
- 27 October 2026
- Published by Frontiers Media SA in Frontiers in Chemistry
- Vol. 14, 1924756
N,S-doped carbon dots derived from tryptophan for sensitive and selective detection of meropenem in live cells, human urine, and water samples
Meropenem (MP) is an important carbapenem antibiotic used as a last-line treatment that requires precise quantification for therapeutic drug monitoring and environmental antibiotic surveillance. Herein, nitrogen, sulfur co-doped carbon dots (N,S-CDs) were derived from L-tryptophan and thiourea for MP detection. The prepared N,S-CDs were characterized by using UV–VIS, X-ray diffraction (XRD), Fourier transform infrared (FT-IR) spectroscopy, high-resolution transmission electron microscopy (HR-TEM), and fluorescence spectroscopy. The interaction with MP led to systematic quenching of fluorescence (λ em = 457 nm, λ ex = 350 nm), a Stern–Volmer constant Ksv = 3.97 × 10 6 M −1 , a binding constant Ka = 9.07 × 10 6 M −1 , and a decrease in the fluorescence lifetime from 6.45 to 5.68 ns. A linear response was exhibited throughout the 0–390 nM range (R 2 = 0.990) with a limit of detection (LOD) of 6.8 nM. The sensor demonstrated high selectivity toward MP with a 1250-fold excess of coexisting inorganic ions, biomolecules, and structurally related carbapenem antibiotics. Intracellular fluorescence imaging and concentration-dependent intracellular MP detection were also demonstrated in live PC3 cells with negligible cytotoxicity (cell viability > 80% up to 10 mg/mL), indicating its potential for clinical therapeutic drug monitoring and environmental surveillance. The probe was successfully validated for the analysis of MP in pharmaceutical formulations, human serum, urine, and environmental water samples, with recoveries (%) in the range of 98%–102%. This work presents N,S-CDs as a robust, sensitive, and biocompatible analytical tool for clinical, pharmacological, and environmental MP surveillance.
- 27 October 2026
- Published by Frontiers Media SA in Frontiers in Chemistry
- Vol. 14, 1924756
Open AccessN,S-doped carbon dots derived from tryptophan for sensitive and selective detection of meropenem in live cells, human urine, and water samples
Meropenem (MP) is an important carbapenem antibiotic used as a last-line treatment that requires precise quantification for therapeutic drug monitoring and environmental antibiotic surveillance. Herein, nitrogen, sulfur co-doped carbon dots (N,S-CDs) were derived from L-tryptophan and thiourea for MP detection. The prepared N,S-CDs were characterized by using UV–VIS, X-ray diffraction (XRD), Fourier transform infrared (FT-IR) spectroscopy, high-resolution transmission electron microscopy (HR-TEM), and fluorescence spectroscopy. The interaction with MP led to systematic quenching of fluorescence (λ em = 457 nm, λ ex = 350 nm), a Stern–Volmer constant Ksv = 3.97 × 10 6 M −1 , a binding constant Ka = 9.07 × 10 6 M −1 , and a decrease in the fluorescence lifetime from 6.45 to 5.68 ns. A linear response was exhibited throughout the 0–390 nM range (R 2 = 0.990) with a limit of detection (LOD) of 6.8 nM. The sensor demonstrated high selectivity toward MP with a 1250-fold excess of coexisting inorganic ions, biomolecules, and structurally related carbapenem antibiotics. Intracellular fluorescence imaging and concentration-dependent intracellular MP detection were also demonstrated in live PC3 cells with negligible cytotoxicity (cell viability > 80% up to 10 mg/mL), indicating its potential for clinical therapeutic drug monitoring and environmental surveillance. The probe was successfully validated for the analysis of MP in pharmaceutical formulations, human serum, urine, and environmental water samples, with recoveries (%) in the range of 98%–102%. This work presents N,S-CDs as a robust, sensitive, and biocompatible analytical tool for clinical, pharmacological, and environmental MP surveillance.
- Open Access
- 26 December 2025
- Published by Springer Nature in BMC Immunology
- Vol. 27 (1)
The relationship between the biological biomarker lnc-DC and female patients with Sjögren’s disease
Laboratory diagnostic markers and clinical presentations of Sjögren’s disease (SjD) may vary by sex. This study aimed to investigate the associa
- 26 December 2025
- Published by Springer Nature in BMC Immunology
- Vol. 27 (1)
Open AccessThe relationship between the biological biomarker lnc-DC and female patients with Sjögren’s disease
Laboratory diagnostic markers and clinical presentations of Sjögren’s disease (SjD) may vary by sex. This study aimed to investigate the associa
- Open Access
- 18 August 2023
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 23 (1) , 1-10
Value of proteinuria in evaluating the severity of HELLP and its maternal and neonatal outcomes
Background: HELLP syndrome refers to a group of clinical syndromes characterized by hemolysis, elevated liver enzymes and low platelet, and the evidence on the association between proteinuria and the severity of HELLP and its maternal and neonatal outcomes is rare. Methods: 106 pregnant women were assigned to the proteinuric group (24-hUPro ≥ 0.3 g, 79 cases) and the non-proteinuric group (24-hUPro < 0.3 g, 27 cases). The proteinuric group was further divided into three subgroups: mild group (24-hUPro:0.3-2.0 g, 33 cases), moderate group (24-hUPro:2.0-5.0 g, 21 cases) and severe group (24-hUPro: ≥5.0 g, 25 cases). The general clinical data, laboratory indexes, complications and pregnancy outcome and adverse neonatal outcomes of HELLP with or without proteinuric were analyzed. Results: Compared with proteinuric group, the non-albuminuric group or in the three proteinuric subgroups of HELLP pregnant women’s, increased proteinuria was associated with earlier onset gestations, higher incidence of abdominal pain, skin jaundice, headache, blurred vision (p < 0.05 respectively), and also the higher levels of ALT, AST, LDH, Fib, APTT, ATII, proportions of tubular urine and lower levels of ALB, PLT (p < 0.05 respectively). In the three subgroups of the proteinuric group, the ratio of fetal growth restriction, cesarean section and postpartum hemorrhage were compared, and the difference was statistically significant (p < 0.05 respectively). Compared with the proteinuric group, the non-proteinuric group had higher birth weight, birth length, and lower SGA, admission rate in NICU (p < 0.05 respectively). In the three subgroups of the proteinuric group, significant differences were identified in the adverse outcomes of newborns (p < 0.05 respectively), and the incidence of adverse outcomes in neonates tended to be higher. Significant differences were identified in birth weight, birth length, and lower SGA and NICU occupancy rate among the three subgroups (p < 0.05 respectively). Conclusions: HELLP syndrome is a severe complication of pregnancy, involving multiple systems of the whole body. It has posed a great challenge to obstetricians for its acute onset, dangerous condition, rapid progress, and great harm. Thus, insights into HELLP syndrome should be gained, and early diagnosis, early treatment and timely termination of pregnancy should be conducted to reduce the incidence of maternal and fetal adverse outcomes and improve maternal and fetal prognosis.
- 18 August 2023
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 23 (1) , 1-10
Open AccessValue of proteinuria in evaluating the severity of HELLP and its maternal and neonatal outcomes
Background: HELLP syndrome refers to a group of clinical syndromes characterized by hemolysis, elevated liver enzymes and low platelet, and the evidence on the association between proteinuria and the severity of HELLP and its maternal and neonatal outcomes is rare. Methods: 106 pregnant women were assigned to the proteinuric group (24-hUPro ≥ 0.3 g, 79 cases) and the non-proteinuric group (24-hUPro < 0.3 g, 27 cases). The proteinuric group was further divided into three subgroups: mild group (24-hUPro:0.3-2.0 g, 33 cases), moderate group (24-hUPro:2.0-5.0 g, 21 cases) and severe group (24-hUPro: ≥5.0 g, 25 cases). The general clinical data, laboratory indexes, complications and pregnancy outcome and adverse neonatal outcomes of HELLP with or without proteinuric were analyzed. Results: Compared with proteinuric group, the non-albuminuric group or in the three proteinuric subgroups of HELLP pregnant women’s, increased proteinuria was associated with earlier onset gestations, higher incidence of abdominal pain, skin jaundice, headache, blurred vision (p < 0.05 respectively), and also the higher levels of ALT, AST, LDH, Fib, APTT, ATII, proportions of tubular urine and lower levels of ALB, PLT (p < 0.05 respectively). In the three subgroups of the proteinuric group, the ratio of fetal growth restriction, cesarean section and postpartum hemorrhage were compared, and the difference was statistically significant (p < 0.05 respectively). Compared with the proteinuric group, the non-proteinuric group had higher birth weight, birth length, and lower SGA, admission rate in NICU (p < 0.05 respectively). In the three subgroups of the proteinuric group, significant differences were identified in the adverse outcomes of newborns (p < 0.05 respectively), and the incidence of adverse outcomes in neonates tended to be higher. Significant differences were identified in birth weight, birth length, and lower SGA and NICU occupancy rate among the three subgroups (p < 0.05 respectively). Conclusions: HELLP syndrome is a severe complication of pregnancy, involving multiple systems of the whole body. It has posed a great challenge to obstetricians for its acute onset, dangerous condition, rapid progress, and great harm. Thus, insights into HELLP syndrome should be gained, and early diagnosis, early treatment and timely termination of pregnancy should be conducted to reduce the incidence of maternal and fetal adverse outcomes and improve maternal and fetal prognosis.
- Open Access
- 16 January 2023
- Published by Springer Nature in Research Square
Value of proteinuria in evaluating the severity of HELLP and its maternal and neonatal outcomes
Background: HELLP syndrome refers to a group of clinical syndromes characterized by hemolysis, elevated liver enzymes and low platelet, and the evidence on the association between proteinuria and the severity of HELLP and its maternal and neonatal outcomes is rare. Methods: 106 pregnant women were assigned to the proteinuric group (24-hUPro ≥0.3 g, 79 cases) and the non-proteinuric group (24-hUProResults: Compared with proteinuricgroup, the non-albuminuric group or in the three proteinuric subgroups of HELLP pregnant women's , increased proteinuria was associated with earlier onset gestations, higher incidence of abdominal pain, skin jaundice, headache, blurred vision (p < 0.05 respectively), and also the higher levels of ALT, AST, LDH, Fib, APTT, ATⅢ, proportions of tubular urine and lower levels of ALB, PLT (p< 0.05 respectively). In the three subgroups of the proteinuric group, the ratio of fetal growth restriction, cesarean section and postpartum hemorrhage were compared, and the difference was statistically significant (p < 0.05 respectively). Compared with the proteinuric group, the non-proteinuric group had higher birth weight, birth length, and lower SGA, admission rate in NICU (p < 0.05 respectively). In the three subgroups of the proteinuric group, significant differences were identified in the adverse outcomes of newborns (p < 0.05 respectively), and the incidence of adverse outcomes in neonates tended to be higher. Significant differences were identified in birth weight, birth length, and lower SGA and NICU occupancy rate among the three subgroups (p < 0.05 respectively). Conclusions: HELLP syndrome is a severe complication of pregnancy, involving multiple systems of the whole body. It has posed a great challenge to obstetricians for its acute onset, dangerous condition, rapid progress, and great harm. Thus, insights into HELLP syndrome should be gained, and early diagnosis, early treatment and timely termination of pregnancy should be conducted to reduce the incidence of maternal and fetal adverse outcomes and improve maternal and fetal prognosis.
- 16 January 2023
- Published by Springer Nature in Research Square
Open AccessValue of proteinuria in evaluating the severity of HELLP and its maternal and neonatal outcomes
Background: HELLP syndrome refers to a group of clinical syndromes characterized by hemolysis, elevated liver enzymes and low platelet, and the evidence on the association between proteinuria and the severity of HELLP and its maternal and neonatal outcomes is rare. Methods: 106 pregnant women were assigned to the proteinuric group (24-hUPro ≥0.3 g, 79 cases) and the non-proteinuric group (24-hUProResults: Compared with proteinuricgroup, the non-albuminuric group or in the three proteinuric subgroups of HELLP pregnant women's , increased proteinuria was associated with earlier onset gestations, higher incidence of abdominal pain, skin jaundice, headache, blurred vision (p < 0.05 respectively), and also the higher levels of ALT, AST, LDH, Fib, APTT, ATⅢ, proportions of tubular urine and lower levels of ALB, PLT (p< 0.05 respectively). In the three subgroups of the proteinuric group, the ratio of fetal growth restriction, cesarean section and postpartum hemorrhage were compared, and the difference was statistically significant (p < 0.05 respectively). Compared with the proteinuric group, the non-proteinuric group had higher birth weight, birth length, and lower SGA, admission rate in NICU (p < 0.05 respectively). In the three subgroups of the proteinuric group, significant differences were identified in the adverse outcomes of newborns (p < 0.05 respectively), and the incidence of adverse outcomes in neonates tended to be higher. Significant differences were identified in birth weight, birth length, and lower SGA and NICU occupancy rate among the three subgroups (p < 0.05 respectively). Conclusions: HELLP syndrome is a severe complication of pregnancy, involving multiple systems of the whole body. It has posed a great challenge to obstetricians for its acute onset, dangerous condition, rapid progress, and great harm. Thus, insights into HELLP syndrome should be gained, and early diagnosis, early treatment and timely termination of pregnancy should be conducted to reduce the incidence of maternal and fetal adverse outcomes and improve maternal and fetal prognosis.